A potential cure for the severe blood disorder beta thalassaemia has given hope to millions. The new gene therapy, Casgevy, is the first of its kind approved for the NHS in England. Patients with beta thalassaemia, who require regular blood transfusions, may now have the chance for a revolutionary treatment using CRISPR gene-editing technology. This therapy could offer a lifetime cure and significantly improve quality of life for those affected. Approval for the therapy has been praised as a beacon of hope for patients by medical professionals and those who have undergone the treatment in clinical trials.